利用天然存在的CD7阴性T细胞进行血液系统恶性肿瘤的免疫治疗
研究利用天然存在的CD7阴性T细胞生成CD7-CAR(CD7-CARCD7-)T细胞,其在体外和异种移植小鼠模型中表现出显著抗肿瘤活性。直接比较显示CD19-CARCD7- T细胞在体外和体内均比未选择的CD19-CAR T细胞具有更强抗肿瘤活性。来自本机构CD19-CAR T细胞临床研究(NCT03573700)的单细胞数据分析显示,CD19-CARCD7lo T细胞存在于初始产物中且输注后可检测到,缓解患者样本中CD7lo T细胞比例高于未缓解者。
要点
- CD7-CARCD7- T细胞以CD4+记忆表型为主,在体外和异种移植小鼠模型中具有显著抗肿瘤活性。
- CD19-CARCD7- T细胞在体外和体内均比未选择的CD19-CAR T细胞抗肿瘤活性更强。
- 本机构CD19-CAR T细胞临床研究(NCT03573700)中,缓解患者样本CD7lo T细胞比例高于未缓解者。
核心结论
- CD7-CARCD7- T细胞具有良好的生物学特性,可能是用于T-ALL和其他血液系统恶性肿瘤过继细胞治疗的有前景的T细胞亚群。
研究设计与样本
- 研究利用天然存在的CD7- T细胞生成CD7-CAR(CD7-CARCD7-)T细胞,并在体外和异种移植小鼠模型中进行评估。
- 研究直接比较了未选择的(bulk)CD19-CAR与CD19-CARCD7- T细胞的抗肿瘤活性。
- 研究挖掘了本机构CD19-CAR T细胞临床研究(NCT03573700)的单细胞基因和T细胞受体(TCR)表达数据集。
主要发现
- CD7-CARCD7- T细胞以CD4+记忆表型为主,在体外慢性抗原暴露和异种移植小鼠模型中具有显著抗肿瘤活性。
- CD19-CARCD7- T细胞在体外和体内均比未选择的CD19-CAR T细胞抗肿瘤活性更强。
- CD19-CARCD7lo T细胞存在于初始CD19-CAR T细胞产物中,输注后可检测到。
- 输注后观察到的唯一功能性CD4+ CD19-CAR T细胞簇表达CD7lo。
- 对治疗有缓解的患者样本中CD7lo T细胞比例高于未缓解者(NCT03573700)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy targeting T-cell acute lymphoblastic leukemia (T-ALL) faces limitations such as antigen selection and limited T-cell persistence. CD7 is an attractive antigen for targeting T-ALL, but overlapping expression on healthy T cells leads to fratricide of CD7-CAR T cells, requiring additional genetic modification. We took advantage of naturally occurring CD7- T cells to generate CD7-CAR (CD7-CARCD7-) T cells. CD7-CARCD7- T cells exhibited a predominantly CD4+ memory phenotype and had significant antitumor activity upon chronic antigen exposure in vitro and in xenograft mouse models. Based on these encouraging results, we next explored the utility of CD7- T cells for the immunotherapy of CD19+ hematological malignancies. Direct comparison of nonselected (bulk) CD19-CAR and CD19-CARCD7- T cells revealed that CD19-CARCD7- T cells had enhanced antitumor activity compared with their bulk counterparts in vitro and in vivo. Lastly, to gain insight into the behavior of CD19-CAR T cells with low levels of CD7 gene expression (CD7lo) in humans, we mined single-cell gene and T-cell receptor (TCR) expression data sets from our institutional CD19-CAR T-cell clinical study. CD19-CARCD7lo T cells were present in the initial CD19-CAR T-cell product and could be detected postinfusion. Intriguingly, the only functional CD4+ CD19-CAR T-cell cluster observed postinfusion exhibited CD7lo expression. Additionally, samples from patients responsive to therapy had a higher proportion of CD7lo T cells than nonresponders (NCT03573700). Thus, CARCD7- T cells have favorable biological characteristics and may present a promising T-cell subset for adoptive cell therapy of T-ALL and other hematological malignancies.
引用
- Freiwan A, Zoine JT, Crawford JC, et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022. PMID: 35914226. doi:10.1182/blood.2021015020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。